Erik is Chairman of Step Pharma and TargED Biopharmaceuticals and co-founder and previous (executive) Chairman of Lava Therapeutics (NASDAQ: LVTX), co-founder and previous (executive) Chairman of Heatmatrix Group (sold to BosNieuwkerk) and was board member of Lead Pharma and the Dutch biotechnology organization. ZURICH-- ( BUSINESS WIRE )-- Memo Therapeutics AG ("MTx"), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as.
Erik van den Berg AM Pharma
Memo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer Mr. van den Berg is an industry veteran with proven track record in building high-performance teams and delivering. ZURICH-- ( BUSINESS WIRE )-- Memo Therapeutics AG ("MTx"), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231115733368/en/ Memo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer Nov 16, 2023 — by Comtex News in Press Releases Memo Therapeutics AG ("MTx"), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO). Schlieren / Zurich, Switzerland - November 16, 2023 - Memo Therapeutics AG ("MTx"), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO). Mr. van den Berg joins MTx with over 25 years' industry experience and proven track record in leading and growing companies.
Erik Van Den Berg Step Pharma
Erik van den Berg 2020-12-02T11:53:26+01:00. Erik van den Berg. Erik has over 20 years of experience in the pharmaceutical industry. He is the CEO of AM-Pharma and board member of several biotech companies. Previously, as a senior executive at Organon (now Merck) he was responsible for leading the company's global biotechnology business. Director, EMEA Erik van den Berg joined IPI's Amsterdam office in July 2021. He was previously an Associate Director at PGGM, focused on global private equity investments in TMT Infrastructure. Erik is Chairman of Step Pharma and co-founder and previous (executive) Chairman of Lava Therapeutics (NASDAQ: LVTX), co-founder and previous (executive) Chairman of Heatmatrix Group (sold to BosNieuwkerk) and was board member of Lead Pharma and the Dutch biotechnology organization. Erik van den Berg on LinkedIn: LAVA Therapeutics and The Antibody Society Present Emerging Cancer… Erik van den Berg's Post Executive, Chairman, Entrepreneur All you wanted to know about gamma.
Erik van den Berg van Berg Makelaardij B.V.
Zürich, Switzerland, November 16, 2023 (Business Wire) -- Memo Therapeutics AG ("MTx"), a late-stage biotech firm advancing top-tier therapeutic antibodies, discloses the appointment of Erik van den Berg as Chief Executive Officer (CEO). Read full article here. January 2023 - TargED is pleased to announce the appointment of Erik van den Berg as Chair of its Supervisory Board. Kristof Vercruysse, CEO of TargED commented: "We are honored to have Erik van den Berg join as independent Chair of the TargED Board.With his extensive experience and outstanding track record in biotechnology business development we are convinced that Erik will be a valuable.
On behalf of the Memo Therapeutics AG team, welcome on-board Erik van den Berg! We are very excited for Erik to support us as #CEO going forward…. Gemarkeerd als interessant door Erik van den Berg. At Step Pharma we selectively target a key enzyme, CTPS1, to stop cancer cells dividing. Our collaborators Christina Pfeiffer and colleagues have…. Schlieren / Zurich, Switzerland - November 16, 2023 - Memo Therapeutics AG ("MTx"), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO). Mr. van den Berg joins MTx with over 25 years' industry experience and proven track record in leading and growing companies.
Erik van den Berg De Nijl Architecten De Nijl Architecten
> Memo Therapeutics has tapped Erik van den Berg to helm the antibody-focused biotech. Van den Berg joins from AM-Pharma, where he was CEO for 12 years, and succeeds Karsten Fischer, who led Memo. Our Chief Executive Officer Erik van den Berg will be at #bioequity Europe 2023 in Dublin May 14-16. Join him at the conference or book a one-on-one meeting to discuss how AM-Pharma is developing.
